HLA-DR Antibody (MHC II)

• Description:

  mAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The mAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This mAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

• UniProt:

  P01903

• Host:

  Mouse

• Immunogen:

  Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the HLA-DR antibody.

• Clonality:

  Monoclonal

• Isotype:

  IgG3 κ

• Applications:

  FACS, IF

• Format:

  Purified

• Buffer:

  0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

• Reconstitution:

  Store the HLA-DR antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

• Limitations:

  This HLA-DR antibody is available for research use only.

• CAS Number:

  9007-83-4